메뉴 건너뛰기




Volumn 23, Issue 1, 2013, Pages 81-89

Immunohistochemical analysis for therapeutic targets and prognostic markers in low-grade endometrial stromal sarcoma

Author keywords

C kit; Ki67; Low grade endometrial stromal sarcoma; P53; PDGFR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; KI 67 ANTIGEN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P16; PROTEIN P53; STEM CELL FACTOR; VASCULOTROPIN;

EID: 84872360535     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182738361     Document Type: Article
Times cited : (22)

References (25)
  • 1
    • 77951239782 scopus 로고    scopus 로고
    • Update on treatment of uterine sarcoma
    • Nam JH, Park JY. Update on treatment of uterine sarcoma. Curr Opin Obstet Gynecol. 2010;22:36-42.
    • (2010) Curr Opin Obstet Gynecol , vol.22 , pp. 36-42
    • Nam, J.H.1    Park, J.Y.2
  • 2
    • 80055026968 scopus 로고    scopus 로고
    • Surgical treatment of uterine sarcoma
    • Nam JH. Surgical treatment of uterine sarcoma. Best Pract Res Clin Obstet Gynaecol. 2011;25:751-760.
    • (2011) Best Pract Res Clin Obstet Gynaecol , vol.25 , pp. 751-760
    • Nam, J.H.1
  • 4
    • 0020416825 scopus 로고
    • Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma
    • Evans HL. Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer. 1982;50:2170-2182.
    • (1982) Cancer. , vol.50 , pp. 2170-2182
    • Evans, H.L.1
  • 5
    • 54949157193 scopus 로고    scopus 로고
    • Prognostic factors and treatment outcomes of patients with uterine sarcoma: Analysis of 127 patients at a single institution, 1989-2007
    • Park JY, Kim DY, Suh DS, et al. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol. 2008;134:1277-1287.
    • J Cancer Res Clin Oncol. , vol.2008 , Issue.134 , pp. 1277-1287
    • Park, J.Y.1    Kim, D.Y.2    Suh, D.S.3
  • 6
    • 83055188443 scopus 로고    scopus 로고
    • The impact of tumor morcellation during surgery on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma of the uterus
    • Park JY, Kim DY, Kim JH, et al. The impact of tumor morcellation during surgery on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma of the uterus. Ann Surg Oncol. 2011;18:3453-3461.
    • (2011) Ann Surg Oncol , vol.18 , pp. 3453-3461
    • Park, J.Y.1    Kim, D.Y.2    Kim, J.H.3
  • 9
    • 15744376982 scopus 로고    scopus 로고
    • Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): Potential basis for a new therapeutic approach
    • Moinfar F, Gogg-Kamerer M, Sommersacher A, et al. Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach. Am J Surg Pathol. 2005;29:485-489.
    • (2005) Am J Surg Pathol , vol.29 , pp. 485-489
    • Moinfar, F.1    Gogg-Kamerer, M.2    Sommersacher, A.3
  • 10
    • 79955481960 scopus 로고    scopus 로고
    • Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy
    • Cheng X, Yang G, Schmeler KM, et al. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol. 2011;121:323-327.
    • (2011) Gynecol Oncol. , vol.121 , pp. 323-327
    • Cheng, X.1    Yang, G.2    Schmeler, K.M.3
  • 11
    • 9944259988 scopus 로고    scopus 로고
    • Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression
    • Geller MA, Argenta P, Bradley W, et al. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. Gynecol Oncol. 2004;95:632-636.
    • (2004) Gynecol Oncol. , vol.95 , pp. 632-636
    • Geller, M.A.1    Argenta, P.2    Bradley, W.3
  • 12
    • 33846900919 scopus 로고    scopus 로고
    • PDGFR-alpha as a potential therapeutic target in uterine sarcomas
    • Adams SF, Hickson JA, Hutto JY, et al. PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol. 2007;104:524-528.
    • (2007) Gynecol Oncol , vol.104 , pp. 524-528
    • Adams, S.F.1    Hickson, J.A.2    Hutto, J.Y.3
  • 13
    • 33750299476 scopus 로고    scopus 로고
    • PDGF-alpha and PDGF-beta are expressed in endometrial stromal sarcoma: A potential therapeutic target for tyrosine kinase inhibitors?
    • Liegl B, Reich O, Nogales FF, et al. PDGF-alpha and PDGF-beta are expressed in endometrial stromal sarcoma: a potential therapeutic target for tyrosine kinase inhibitors? Histopathology. 2006;49:545-546.
    • (2006) Histopathology , vol.49 , pp. 545-546
    • Liegl, B.1    Reich, O.2    Nogales, F.F.3
  • 14
    • 19444373545 scopus 로고    scopus 로고
    • Imatinib mesylate (gleevec)Ytargeted kinases are expressed in uterine sarcomas
    • Caudell JJ, Deavers MT, Slomovitz BM, et al. Imatinib mesylate (gleevec)Ytargeted kinases are expressed in uterine sarcomas. Appl Immunohistochem Mol Morphol. 2005;13:167-170.
    • (2005) Appl Immunohistochem Mol Morphol , vol.13 , pp. 167-170
    • Caudell, J.J.1    Deavers, M.T.2    Slomovitz, B.M.3
  • 15
    • 44349166828 scopus 로고    scopus 로고
    • KIT protein expression in uterine sarcomas: An immunohistochemical study and review of the literature
    • Zafrakas M, Theodoridis TD, Zepiridis L, et al. KIT protein expression in uterine sarcomas: an immunohistochemical study and review of the literature. Eur J Gynaecol Oncol. 2008;29:264-266.
    • (2008) Eur J Gynaecol Oncol , vol.29 , pp. 264-266
    • Zafrakas, M.1    Theodoridis, T.D.2    Zepiridis, L.3
  • 16
    • 0037378396 scopus 로고    scopus 로고
    • Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary
    • Klein WM, Kurman RJ. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int J Gynecol Pathol. 2003;22:181-184.
    • (2003) Int J Gynecol Pathol , vol.22 , pp. 181-184
    • Klein, W.M.1    Kurman, R.J.2
  • 17
    • 16544371910 scopus 로고    scopus 로고
    • Prevalence of KIT expression in human tumors
    • Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol. 2004;22:4514-4522.
    • (2004) J Clin Oncol. , vol.22 , pp. 4514-4522
    • Went, P.T.1    Dirnhofer, S.2    Bundi, M.3
  • 18
    • 1242318769 scopus 로고    scopus 로고
    • Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: A case series
    • Leath CA 3rd, Straughn JM Jr, Conner MG, et al. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series. J Reprod Med. 2004;49:71-75.
    • (2004) J Reprod Med , vol.49 , pp. 71-75
    • Leath Iii, C.A.1    Straughn Jr., J.M.2    Conner, M.G.3
  • 20
    • 0141757485 scopus 로고    scopus 로고
    • Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT
    • Rushing RS, Shajahan S, Chendil D, et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol Oncol. 2003;91:9-14.
    • (2003) Gynecol Oncol , vol.91 , pp. 9-14
    • Rushing, R.S.1    Shajahan, S.2    Chendil, D.3
  • 21
    • 33847320613 scopus 로고    scopus 로고
    • Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations
    • Liegl B, Gully C, Reich O, et al. Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations. Histopathology. 2007;50:448-452.
    • (2007) Histopathology , vol.50 , pp. 448-452
    • Liegl, B.1    Gully, C.2    Reich, O.3
  • 22
    • 84857672358 scopus 로고    scopus 로고
    • Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro
    • Bilir A, Erguven M, Ermis E, et al. Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro. J Gynecol Oncol. 2011;22:225-232.
    • (2011) J Gynecol Oncol. , vol.22 , pp. 225-232
    • Bilir, A.1    Erguven, M.2    Ermis, E.3
  • 23
    • 58249127460 scopus 로고    scopus 로고
    • Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma
    • Kalender ME, Sevinc A, Yilmaz M, et al. Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma. Cancer Chemother Pharmacol. 2009;63:555-559.
    • (2009) Cancer Chemother Pharmacol , vol.63 , pp. 555-559
    • Kalender, M.E.1    Sevinc, A.2    Yilmaz, M.3
  • 24
    • 33846208614 scopus 로고    scopus 로고
    • KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate
    • Mitsuhashi T, Nakayama M, Sakurai S, et al. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate. Ann Diagn Pathol. 2007;11:49-54.
    • (2007) Ann Diagn Pathol , vol.11 , pp. 49-54
    • Mitsuhashi, T.1    Nakayama, M.2    Sakurai, S.3
  • 25
    • 33646739922 scopus 로고    scopus 로고
    • A case of c-kit positive high-grade stromal endometrial sarcoma responding to imatinib mesylate
    • Salvatierra A, Tarrats A, Gomez C, et al. A case of c-kit positive high-grade stromal endometrial sarcoma responding to imatinib mesylate. Gynecol Oncol. 2006;101:545-547.
    • (2006) Gynecol Oncol. , vol.101 , pp. 545-547
    • Salvatierra, A.1    Tarrats, A.2    Gomez, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.